OrganiGram Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
View analyst ratings for OrganiGram or view top-rated stocks.

Wall Street analysts have given OrganiGram a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OrganiGram wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

OrganiGram saw a decrease in short interest in the month of May. As of May 28th, there was short interest totaling 11,890,000 shares, a decrease of 13.6% from the May 13th total of 13,760,000 shares. Based on an average daily trading volume, of 11,930,000 shares, the days-to-cover ratio is presently 1.0 days.
View OrganiGram's Short Interest.

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, July 20th 2021.
View our earnings forecast for OrganiGram.

OrganiGram Holdings Inc. (NASDAQ:OGI) released its quarterly earnings results on Monday, April, 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.26. The firm had revenue of $11.49 million for the quarter, compared to the consensus estimate of $15.70 million. OrganiGram had a negative trailing twelve-month return on equity of 19.11% and a negative net margin of 315.91%.
View OrganiGram's earnings history.

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OGI shares have increased by 76.7% and is now trading at $3.04.
View which stocks have been most impacted by COVID-19.

11 brokers have issued 1-year price objectives for OrganiGram's stock. Their forecasts range from $3.50 to $6.00. On average, they expect OrganiGram's share price to reach $4.47 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price.
View analysts' price targets for OrganiGram or view top-rated stocks among Wall Street analysts.

Some companies that are related to OrganiGram include Intra-Cellular Therapies (ITCI), Emergent BioSolutions (EBS), Sage Therapeutics (SAGE), Cassava Sciences (SAVA), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Insmed (INSM), Taro Pharmaceutical Industries (TARO), Cryoport (CYRX), Rocket Pharmaceuticals (RCKT), Dicerna Pharmaceuticals (DRNA), Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX) and IGM Biosciences (IGMS).
View all of OGI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), The Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

OrganiGram's stock is owned by many different institutional and retail investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (1.35%), Millennium Management LLC (1.13%), Penserra Capital Management LLC (0.42%), TD Asset Management Inc. (0.27%), Bank of Montreal Can (0.19%) and Swiss National Bank (0.18%).

OGI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Scotia Capital Inc., Sigma Planning Corp, Walleye Capital LLC, and Creative Planning.

OGI stock was purchased by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., TD Asset Management Inc., Penserra Capital Management LLC, Bank of Montreal Can, Morgan Stanley, HRT Financial LP, Squarepoint Ops LLC, and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp.

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OGI stock can currently be purchased for approximately $3.04.

OrganiGram has a market capitalization of $906.64 million and generates $64.61 million in revenue each year. The company earns $-101,290,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

OrganiGram employs 619 workers across the globe.

The official website for OrganiGram is www.organigram.ca.

OrganiGram is headquartered at 35 English Dr., Moncton Z4, E1E 3X3.

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.